Please login to the form below

Not currently logged in

Hospira’s oncology drug approved by FDA

Hospira gains approval from the FDA for new oncology drug, gemcitabine injection

The US Food and Drug Administration (FDA) has approved a new oncology drug by Hospira.

The approval was for gemcitabine injection, a solution form of the drug. The company says that this solution form reduces preparation time and gives the medical community “access to a lower-cost, more convenient offering” of the oncology drug. 

Hospira is hoping to launch the product by early September, and will be the first company to offer gemcitabine in a solution formulation for the US market. 

The concentration of the solution is the same as the reconstituted strength of the currently available “freeze-dried” form, but will eliminate the need for reconstitution, thus improving work flow, according to the company.

Hospira hopes that it will also improve pharmacist convenience and handling safety. 

8th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....